Editas Medicine (EDIT) Asset Utilization Ratio (2016 - 2025)
Editas Medicine (EDIT) posted quarterly Asset Utilization Ratio of 0.22 for Q3 2025, up 29.75% year-over-year from 0.17 in Q3 2024, and up 37.13% quarter-over-quarter from 0.16 in Q2 2025.
Editas Medicine (EDIT) Asset Utilization Ratio (2016 - 2025) Analysis & Trends
Editas Medicine (EDIT) has reported Asset Utilization Ratio for 10 consecutive years, with 0.22 the latest figure, recorded in Q3 2025.
- In Q3 2025, Asset Utilization Ratio rose 29.75% year-over-year to 0.22; the TTM figure through Sep 2025 stood at 0.22 (up 29.75% YoY), while the FY2024 annual figure was 0.08, down 50.14% from the prior year.
- Asset Utilization Ratio rose to 0.22 in Q3 2025 per EDIT's latest filing, from 0.16 in the prior quarter.
- Across five years, Asset Utilization Ratio topped out at 0.22 in Q3 2025 and bottomed at 0.03 in Q3 2021.
- Historically, Asset Utilization Ratio has averaged 0.1 across 5 years, with a median of 0.1 in 2024.
- Annual changes were most pronounced in 2021 — Asset Utilization Ratio tumbled 77.26% — and 2024, when it jumped 323.12%.
- Editas Medicine's Asset Utilization Ratio stood at 0.04 in 2021, then gained by 2.94% to 0.04 in 2022, then soared by 312.75% to 0.16 in 2023, then sank by 37.95% to 0.1 in 2024, then surged by 132.95% to 0.22 in 2025.
- Business Quant data shows EDIT's Asset Utilization Ratio at 0.22 in Q3 2025, 0.16 in Q2 2025, and 0.12 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Asset Util. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 0.47 |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 0.38 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 0.69 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 186.67 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.13 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 0.90 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 0.54 |
| 10 | Editas Medicine | 263.01 Mn | 116.36 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 0.22 |
| Jun 30, 2025 | 0.16 |
| Mar 31, 2025 | 0.12 |
| Dec 31, 2024 | 0.10 |
| Sep 30, 2024 | 0.17 |
| Jun 30, 2024 | 0.16 |
| Mar 31, 2024 | 0.15 |
| Dec 31, 2023 | 0.16 |
| Sep 30, 2023 | 0.05 |
| Jun 30, 2023 | 0.04 |
| Mar 31, 2023 | 0.05 |
| Dec 31, 2022 | 0.04 |
| Sep 30, 2022 | 0.05 |
| Jun 30, 2022 | 0.05 |
| Mar 31, 2022 | 0.04 |
| Dec 31, 2021 | 0.04 |
| Sep 30, 2021 | 0.03 |
| Jun 30, 2021 | 0.11 |
| Mar 31, 2021 | 0.14 |
| Dec 31, 2020 | 0.16 |